Xinlong Ma

Dr. Xinlong Ma


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
XMXinlong Ma
Xinlong Ma
XMXinlong Ma
Xinlong Ma
JMJianxiong Ma
Jianxiong Ma
XSXiaolei Sun
Xiaolei Sun
FLFengbo Li
Fengbo Li
JLJianwei Lv
Jianwei Lv

1 January 2017 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
NSNan Song
Nan Song
XMXinlong Ma
Xinlong Ma
XMXinlong Ma
Xinlong Ma
XSXiaolei Sun
Xiaolei Sun
JMJianxiong Ma
Jianxiong Ma
JLJianwei Lv
Jianwei Lv

28 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYan Zhang
Yan Zhang
KHKun Huang
Kun Huang
DXDejian Xie
Dejian Xie
JLJian You Lau
Jian You Lau
WSWenlong Shen
Wenlong Shen
XMXinlong Ma
Xinlong Ma
The dynamics of SARS-CoV-2 RNA structure and their functional relevance are largely unknown. Here we develop a simplified SPLASH assay and comprehensively map the in vivo RNA-RNA interactome of SARS-CoV-2 genome across viral life cycle. We report canonical and alternative structures including 5′-UTR and 3′-UTR, frameshifting element (FSE) pseudoknot and genome cyclization in both cells and virions. We provide direct evidence of interactions between Transcription Regulating Sequences, which facilitate discontinuous transcription. In addition, we reveal alternative short and long distance arches around FSE. More importantly, we find that within virions, while SARS-CoV-2 genome RNA undergoes intensive compaction, genome domains remain stable but with strengthened demarcation of local domains and weakened global cyclization. Taken together, our analysis reveals the structural basis for the regulation of replication, discontinuous transcription and translational frameshifting, the alternative conformations and the maintenance of global genome organization during the whole life cycle of SARS-CoV-2, which we anticipate will help develop better antiviral strategies.

13 January 2020 in Arthroscopy
Verified
Journal Article
Closed access
XMXinlong Ma
Xinlong Ma
JMJian‐Xiong Ma
Jian‐Xiong Ma
XMXin‐Long Ma
Xin‐Long Ma

19 May 2021 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
XMXinlong Ma
Xinlong Ma
XMXinlong Ma
Xinlong Ma
BZBin Zhao
Bin Zhao
PTPeng Tian
Peng Tian
JMJian‐Xiong Ma
Jian‐Xiong Ma
LSLei Sun
Lei Sun
Objectives: Large bone defects are a common, debilitating clinical condition that have substantial global health and economic burden. Bone tissue engineering technology has become one of the most promising approaches for regenerating defective bones. In this study, we fabricated a naringin‐inlaid composite silk fibroin/hydroxyapatite (NG/SF/HAp) scaffold to repair bone defects.Materials and Methods: The salt‐leaching technology was used to fabricate the NG/SF/HAp scaffold. The cytocompatibility of the NG/SF/HAp scaffold was assessed using scanning electron microscopy, live/dead cell staining and phalloidin staining. The osteogenic and angiogenic properties were assessed in vitro and in vivo.Results: The porous NG/SF/HAp scaffold had a well‐designed biomimetic porous structure with osteoinductive and angiogenic activities. A gene microarray identified 854 differentially expressed genes between human umbilical cord‐derived mesenchymal stem cells (hUCMSCs) cultured on SF‐nHAp scaffolds and cells cultured on NG/SF/HAp scaffolds. The underlying osteoblastic mechanism was investigated using hUCMSCs in vitro. Naringin facilitated hUCMSC ingrowth into the SF/HAp scaffold and promoted osteogenic differentiation. The osteogenic and angiogenic capabilities of cells cultured in the NG/SF/HAp scaffold were superior to those of cells cultured in the SF/HAp scaffold.Conclusions: The data indicate the potential of the SF/HAp composite scaffold incorporating naringin for bone regeneration.

1 November 2015 in Medicine
Verified
Journal Article
Open access
XSXiao-Lei Sun
Xiao-Lei Sun
XMXinlong Ma
Xinlong Ma
JMJian-Xiong Ma
Jian-Xiong Ma
FLFeng-Bo Li
Feng-Bo Li
YLYan-Jun Li
Yan-Jun Li
XMXin-Long Ma
Xin-Long Ma
A total knee arthroplasty (TKA) has always been associated with moderate to severe pain. As more research is conducted on the use of continuous local infiltration analgesia (CLIA) to manage pain after a TKA, it is necessary to reassess the efficacy and safety of the TKA method. The purpose of this systematic review and meta-analysis of randomized controlled trials was to evaluate the efficacy and safety of pain control of CLIA versus placebo after a TKA. In January 2015, a systematic computer-based search was conducted in the Medline, Embase, PubMed, CENTRAL (Cochrane Controlled Trials Register), Web of Science, Google database, and Chinese Wanfang databases. This systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement criteria. The primary endpoint was the visual analog scale score after a TKA with rest or mobilization at 24, 48, and 72 hours, which represents the effect of pain control after TKA. The complications of infection, nausea, and whether it prolonged wound drainage were also compiled to assess the safety of CLIA. RevMan 5.30 software was used for the meta-analysis. After testing for publication bias and heterogeneity across studies, data were aggregated for random-effects modeling when necessary. Ten studies involving 735 patients met the inclusion criteria. The meta-analysis revealed that continuous infusion analgesia provided better pain control with rest at 24 hours (mean difference [MD] -12.54, 95% confidence interval [CI] -16.63 to 8.45), and with mobilization at 24 hours (MD -18.27, 95% CI -27.52 to 9.02) and 48 hours (MD -14.19, 95% CI -21.46 to 6.93). There was no significant difference with respect to the visual analog scale score at 48 hours (MD -6.15, 95% CI -13.51 to 1.22, P = 0.10) and 72 hours (MD -3.63, 95% CI -10.43 to 3.16, P = 0.29) with rest and at 72 hours with mobilization (MD -4.25, 95% CI -16.27 to 7.77, P = 0.49). However, CLIA increased the rate of infection (relative risk [RR] 3.16, 95% CI 1.18-8.50, P = 0.02) and the rate of nausea or vomiting (RR 0.60, 95% CI 0.37-0.96, P = 0.03). There were no significant differences in the length of hospital stay (MD -0.34, 95% CI -1.09 to 0.42, P = 0.38), deep venous thrombosis (RR 1.02, 95% CI 0.30 to 1.41, P = 0.99), or duration of surgery (MD 1.20, 95% CI -4.59 to 6.98, P = 0.69). On the basis of the current meta-analysis, CLIA was more efficacious for reducing postoperative pain than the placebo at 24 hours with rest and at 24 and 48 hours with mobilization, but it increased the risk of infection. However, CLIA did not prolong the length of hospital stay or the duration of surgery. There was also a higher heterogeneity of different analgesic drugs mixed and a high risk of selection bias in this analysis; therefore, more high-quality randomized controlled trials with standardized CLIA are necessary for proper comparisons of this technique with other methods.